[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600129":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":38,"locations":44,"responsibleParty":55,"collaborators":31,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":31,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":31,"enrollmentInfo":66,"targetDuration":31,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":31,"overallStatus":46,"whyStopped":31,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Celltrion","INDUSTRY",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group 1","ACTIVE_COMPARATOR","Metformin + Alogliptin + Empagliflozin Xmg",[13,14,15],"Drug: Metformin","Drug: Alogliptin","Drug: empagliflozin",{"label":17,"type":10,"description":18,"interventionNames":19},"Study group 2","Metformin + Alogliptin + Empagliflozin Ymg",[13,14,15],{"label":21,"type":22,"description":23,"interventionNames":24},"Control Group","PLACEBO_COMPARATOR","Metformin + Alogliptin",[13,14],[26,32,35],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Metformin","tablets, QD, oral administration",[21,9,17],null,{"type":27,"name":33,"description":29,"armGroupLabels":34,"otherNames":31},"Alogliptin",[21,9,17],{"type":27,"name":36,"description":29,"armGroupLabels":37,"otherNames":31},"empagliflozin",[9,17],[39],{"name":40,"role":41,"phone":42,"phoneExt":31,"email":43},"Celltrion, Inc.","CONTACT","+82 3403 9647","sanghee.byun@celltrion.com",[45],{"facility":5,"status":46,"city":47,"state":31,"zip":31,"country":48,"countryCode":31,"cosmosGeoPoint":49,"geoPoint":54,"contacts":31},"RECRUITING","Seoul","South Korea",{"type":50,"coordinates":51},"Point",[52,53],126.9784,37.566,{"lat":53,"lon":52},{"type":56,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100600129","phase-3-efficacy-and-safety-of-add-on-therapy-with-empagliflozin-in-patients-with-type-2-diabetes-on-a-background-of-alogliptin-and-metformin-100600129",false,"NCT07093476","Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin","Inclusion Criteria:\n\n* Adults at the time of signing the Informed Consent Form (ICF)\n* Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study\n* Diagnosed with T2DM\n\nExclusion Criteria:\n\n* Diagnosed with other types of diabetes than T2DM\n* History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy\n* Uncontrolled severe complications of diabetes","ALL","19 Years",{"count":67,"type":68},171,"ESTIMATED","INTERVENTIONAL",[71],"PHASE3","Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.",[74,75,76],"T2DM","Diabete Type 2","DM","2025-08-07",{"date":79,"type":80},"2025-08-11","ACTUAL",{"date":82,"type":80},"2025-07-18",{"date":84,"type":68},"2027-04",{"name":5,"class":6},1]